EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma

Daniel P de Bruyn, Natasha M van Poppelen, Tom Brands, Susanne C van den Boom, Ellis Eikenboom, Anja Wagner, Monique M van Veghel-Plandsoen, Geert Geeven, Berna Beverloo, Caroline M van Rij, Robert M Verdijk, Nicole C Naus und 5 weitere

Investigative Opthalmology & Visual Science · 2024

DOI: 10.1167/iovs.65.2.11 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Investigative Opthalmology & Visual Science, 2024. Verfasst von Daniel P de Bruyn und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Melanoma, Uveal Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Uveal melanoma (UM) has a high propensity to metastasize. Prognosis is associated with specific driver mutations and copy number variations (CNVs), but limited primary tumor tissue is available for molecular characterization due to eye-sparing irradiation treatment. This study aimed to assess the rise in circulating tumor DNA (ctDNA) levels in UM and evaluate its efficacy for CNV-profiling of patients with UM.

Methods

In a pilot study, we assessed ctDNA levels in the blood of patients with UM (n = 18) at various time points, including the time of diagnosis (n = 13), during fractionated stereotactic radiotherapy (fSRT) treatment (n = 6), and upon detection of metastatic disease (n = 13). Shallow whole-genome sequencing (sWGS) combined with in silico size-selection was used to identify prognostically relevant CNVs in patients with UM (n = 26) from peripheral blood retrieved at the time of diagnosis (n = 9), during fSRT (n = 5), during post-treatment follow-up (n = 4), metastasis detection (n = 6), and metastasis follow-up (n = 4).

Results

A total of 34 patients had blood analyzed for ctDNA detection (n = 18) and/or CNV analysis (n = 26) at various time points. At the time of diagnosis, 5 of 13 patients (38%) had detectable ctDNA (median = 0 copies/mL). Upon detection of metastatic disease, ctDNA was detected in 10 of 13 patients (77%) and showed increased ctDNA levels (median = 24 copies/mL, P 0.05). The ctDNA fractions were undetectable to low in localized disease, and sWGS did not elucidate chromosome 3 status from blood samples. However, in 7 of 10 (70%) patients with metastases, the detection of chromosome 3 loss corresponded to the high metastatic-risk class.

Conclusions

The rise in ctDNA levels observed in patients with UM harboring metastases suggests its potential utility for CNV profiling. These findings highlight the potential of using ctDNA for metastasis detection and patient inclusion in therapeutic studies targeting metastatic UM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAMelanomaUveal NeoplasmsHumansDNA Copy Number VariationsPilot ProjectsBiomarkersUveal Melanoma

Substanzen

Circulating Tumor DNABiomarkers

Autor:innen und Institutionen

  • Department of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands.
  • Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Radiation Oncology, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Pathology, Section Ophthalmic Pathology, Erasmus MC, Rotterdam, The Netherlands.
  • Department of Pathology, LUMC, Leiden, The Netherlands.

Zitieren

APA

de Bruyn, D. P., van Poppelen, N. M., Brands, T., van den Boom, S. C., Eikenboom, E., Wagner, A., van Veghel-Plandsoen, M. M., Geeven, G., Beverloo, B., van Rij, C. M., Verdijk, R. M., Naus, N. C., Bagger, M. M., Kiilgaard, J. F., de Klein, A., Brosens, E., & Kiliç, E. (2024). Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma. Investigative Opthalmology & Visual Science. https://doi.org/10.1167/iovs.65.2.11

Vancouver

de Bruyn DP, van Poppelen NM, Brands T, van den Boom SC, Eikenboom E, Wagner A, et al. Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma. Investigative Opthalmology & Visual Science. 2024. doi:10.1167/iovs.65.2.11

BibTeX
@article{deBruyn2024,
  author = {de Bruyn, Daniel P and van Poppelen, Natasha M and Brands, Tom and van den Boom, Susanne C and Eikenboom, Ellis and Wagner, Anja and van Veghel-Plandsoen, Monique M and Geeven, Geert and Beverloo, Berna and van Rij, Caroline M and Verdijk, Robert M and Naus, Nicole C and Bagger, Mette M and Kiilgaard, Jens F and de Klein, Annelies and Brosens, Erwin and Kiliç, Emine},
  title = {Evaluation of Circulating Tumor DNA as a Liquid Biomarker in Uveal Melanoma},
  journal = {Investigative Opthalmology & Visual Science},
  year = {2024},
  doi = {10.1167/iovs.65.2.11}
}
Kostenlos starten →